XML 16 R6.htm IDEA: XBRL DOCUMENT v3.25.3
Statement of Consolidated Cash Flows (unaudited) - USD ($)
$ in Millions
9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Operating activities    
Net income $ 1,136 $ 841
Adjustments to reconcile net income to cash provided from operations:    
Depreciation and amortization 210 204
Deferred income taxes 75 39
Restructuring and other (credits) charges (4) 21
Net realized and unrealized losses 17 18
Net periodic pension cost (E) 31 31
Stock-based compensation 59 54
Loss on debt redemption (N) 0 6
Other 3 4
Changes in assets and liabilities, excluding effects of acquisitions, divestitures, and foreign currency translation adjustments:    
Increase in receivables (J) (180) (97)
Increase in inventories (K) (95) (139)
(Increase) decrease in prepaid expenses and other current assets (11) 9
Increase (decrease) in accounts payable, trade 17 (67)
Decrease in accrued expenses (2) (42)
Decrease in taxes, including income taxes (3) (5)
Pension contributions (30) (33)
Increase in noncurrent assets (6) (6)
Increase (decrease) in noncurrent liabilities 13 (20)
Cash provided from operations 1,230 818
Financing Activities    
Additions to debt (N) 0 500
Repurchases and payments on debt (N) (140) (805)
Debt issuance costs (N) 0 (5)
Premiums paid on early redemption of debt (N) 0 (5)
Repurchases of common stock (500) (310)
Proceeds from exercise of employee stock options 1 7
Dividends paid to shareholders (131) (76)
Taxes paid for net share settlement of equity awards (45) (48)
Other (5) 0
Cash used for financing activities (820) (742)
Investing Activities    
Capital expenditures (C) (329) (219)
Proceeds from the sale of assets and businesses (D) 9 9
Additions to investments (9) 0
Sale of investments 13 0
Other 0 1
Cash used for investing activities (316) (209)
Effect of exchange rate changes on cash, cash equivalents and restricted cash 1 (2)
Net change in cash, cash equivalents and restricted cash 95 (135)
Cash, cash equivalents and restricted cash at beginning of period 565 610
Cash, cash equivalents and restricted cash at end of period $ 660 $ 475